US 12,410,477 B2
Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders
David A. Schwartz, Aurora, CO (US); and Max Seibold, Denver, CO (US)
Assigned to National Jewish Health, Denver, CO (US)
Filed by National Jewish Health, Denver, CO (US)
Filed on Apr. 25, 2023, as Appl. No. 18/306,648.
Application 18/306,648 is a continuation of application No. 17/091,507, filed on Nov. 6, 2020, granted, now 11,649,503.
Application 17/091,507 is a continuation of application No. 15/802,281, filed on Nov. 2, 2017, granted, now 10,858,707, issued on Dec. 8, 2020.
Application 15/802,281 is a continuation of application No. 15/217,885, filed on Jul. 22, 2016, abandoned.
Application 15/217,885 is a continuation of application No. 14/171,536, filed on Feb. 3, 2014, abandoned.
Application 14/171,536 is a continuation of application No. 13/014,589, filed on Jan. 26, 2011, granted, now 8,673,565, issued on Feb. 26, 2014.
Claims priority of provisional application 61/323,760, filed on Apr. 13, 2010.
Claims priority of provisional application 61/323,238, filed on Apr. 12, 2010.
Claims priority of provisional application 61/298,814, filed on Jan. 27, 2010.
Claims priority of provisional application 61/298,473, filed on Jan. 26, 2010.
Prior Publication US 2023/0313307 A1, Oct. 5, 2023
Int. Cl. C12Q 1/6883 (2018.01); C12Q 1/6813 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/6813 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/172 (2013.01); G01N 2333/4725 (2013.01); G01N 2800/12 (2013.01)] 2 Claims
 
1. A method of treating idiopathic pulmonary fibrosis in a human subject in need thereof, the method comprising:
(i) obtaining a lung tissue sample from the human subject;
(ii) detecting an elevated level of MUC5B mRNA in the lung tissue sample, relative to the level of MUC5B mRNA in control lung tissue samples obtained from human subjects unaffected by pulmonary fibrosis;
(iii) identifying the human subject having the elevated level of MUC5B mRNA in the lung tissue sample as having idiopathic pulmonary fibrosis; and
(iv) administering to the human subject having idiopathic pulmonary fibrosis an effective amount of a mucolytic agent.